Skip to main content
BOVNF logo

BioInvent International AB (publ) (BOVNF) Stock Price & Analysis

BioInvent International AB (publ) (BOVNF) — price $0.2798 (0.00%), as of the Nov 19, 2026 trading session; market cap $18.4M.

Educational signal · not a buy or sell recommendation · How to read this

$0.2798 $0.00 (0.00%) Market Cap $18.4M

BioInvent International AB (publ) · BOVNF

BioInvent International AB is a clinical-stage biotechnology company based in Sweden. They focus on discovering and developing immuno-modulatory antibodies for cancer treatment, with a lead drug candidate targeting non-Hodgkin lymphoma and solid tumors.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.2798
Change on the day0.00%
52-week range$0.2798 – $3.29
Market capitalisation$18.4M
Shares traded on the day5.0K

Price & events

Other perspectives

Council score for BioInvent International AB (publ) (BOVNF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

1 lens, 1 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Neutral read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is BioInvent International AB (publ) (BOVNF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BioInvent International AB (publ) (BOVNF) is the company analyzed here. It employs 109 people and is led by Martin Welschof. In Q3 FY2026 it reported revenue of kr11M and net income of -kr119M. The market values it at $18.4M.

2 · Latest results

What do the latest results show for BioInvent International AB (publ) (BOVNF)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of kr11M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026kr11M-kr119M-kr1.81 (diluted)
Q2 FY2026kr13M-kr123M-kr1.87 (diluted)
Q1 FY2026kr13M-kr119M-kr1.81 (diluted)
Q4 FY2025kr3M-kr126M-kr1.92 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for BioInvent International AB (publ) (BOVNF)?

Short answer · as of

The distress and quality screens read Altman Z -3.43 · Piotroski F 3. Trailing ratios: current ratio 2.80.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -3.43 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BOVNF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported BOVNF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about BioInvent International AB (publ) (BOVNF)?

Read these with our analysis →

What Investors Ask About BioInvent International AB (publ) (BOVNF)

These answers are editorial: 1 of these 8 answers is drawn from the BOVNF research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is BOVNF a good stock to buy?

Stock Expert AI does not rate BOVNF buy, sell or hold. BioInvent International AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the BOVNF stock price today?

The last price recorded for BioInvent International AB (publ) (BOVNF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for BOVNF?

The main risks for BioInvent International AB (publ) include the uncertainty of clinical trial outcomes, competition from other biotechnology and pharmaceutical companies, and regulatory hurdles in drug approval. As a clinical-stage company, BioInvent is heavily reliant on the success of its drug candidates in clinical trials.

What are the key factors to evaluate for BOVNF?

Evaluate BOVNF on fundamentals, analyst consensus, and risk factors. Pursuing further collaborations will be crucial for long-term growth and success. Not financial advice.

How frequently does BOVNF data refresh on this page?

BOVNF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven BOVNF's recent stock price performance?

BioInvent International AB (publ) (BOVNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative immuno-oncology pipeline with novel drug candidates. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider BOVNF overvalued or undervalued right now?

BioInvent International AB (publ) (BOVNF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research BOVNF before investing?

Before investing in BioInvent International AB (publ) (BOVNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.